Professor Phan |
In a
landmark randomised control trial published in The New England Journal of Medicine and presented at the American Stroke Association’s
International Conference last week, researchers from Royal Melbourne Hospital and their
collaborators at Monash University and Monash
Health have shown
significantly improved outcomes for stroke patients.
Stroke is
the second single greatest killer and one of the leading causes of disability
amongst adults in Australia and worldwide. Eighty per cent of all strokes are caused
by a blood clot blocking a blood vessel in the brain, known as an ischaemic
stroke.
“We know
that ischaemic stroke patients have improved outcomes when treated with a clot
busting drug given intravenously within 4.5 hours of stroke onset,” said Monash
University researcher and Head of Stroke at Monash Health, Professor Thanh Phan.
“However,
intravenous clot-busting drugs alone may not be effective enough if there is a very
large clot blocking a major brain artery,” added Professor Phan. “And bigger clots cause bigger damage.”
“Our
study has shown for the first time that an intervention known as stent-thrombectomy
in addition to an intravenous clot-busting drug leads to significantly better outcomes for
patients with large clot blockages.”
Stent-thrombectomy is a minimally invasive procedure performed via an
angiogram (an x-ray procedure where dye is injected into the arteries to
visualise the clot). A radiologist inserts a small tube (stent) via an artery
in the groin and feeds it up into the brain to capture and remove the offending
clot with a specialised retriever device.
Earlier randomised
clinical trials using such devices were inconclusive. However, these studies used older devices,
had longer times to treatment, as well as a lack of advanced imaging methods to
identify the blockage and brain at risk.
“The
success of this trial is likely due to better patient selection through the use
of advanced imaging to detect salvageable brain tissue, blood vessel occlusion,
as well as earlier time to treatment,” said Professor Phan.
This
finding is in line with the Dutch MRCLEAN trial, published in the January issue
of the same journal.
Lead
researcher, Dr Bruce Campbell from the Royal Melbourne Hospital reported the
significant findings of the Australian trial in The New England
Journal of Medicine. Just 24 hours after suffering a stroke, the rate of
re-opening of the blocked artery increased from 32 per cent in the group
receiving the clot busting drug alone to 89 per cent in the group receiving
both the clot busting drug and the intervention using the stent-retriever
device. After three months, only 40 per cent of the group who received the clot
busting drug alone had recovered their independence compared to 71 per cent in
the group treated with the combined
intervention.
Notably,
there were no safety issues such as excessive bleeding in the brain with the
device treatment.
“It is
estimated from this trial that 10 per cent of patients undergoing clot busting
therapy will also require this specialised treatment,” said Professor Phan.
In many countries, including
Australia, there are a limited number of hospitals that can provide
stent-thrombectomy and a limited number of specialists are trained to perform
the procedure. Currently many patients have to be transferred between
hospitals.
“An
important implication from this trial is that patients with large clot blockages
will need to be transferred to tertiary referral centres such as the Royal
Melbourne Hospital and Monash Medical Centre,” added Professor Phan.
“This may
have implications for health funding as selected hospitals will need to be
designated as referral centres with appropriate resources in order to provide
this type of therapy.”
The
Monash team included members of the Stroke & Ageing Research Group at Monash University and the
Stroke Unit, Monash Health (Professor Thanh Phan, Dr Henry Ma) and the
Radiology Department at Monash Health (Associate Professor Winston Chong,
Associate Professor Ronil Chandra).
No comments:
Post a Comment